Marker Therapeutics (MRKR) Projected to Post Quarterly Earnings on Thursday

Marker Therapeutics (NASDAQ:MRKR) is expected to be announcing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $0.6820 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 9:30 AM ET.

Marker Therapeutics Stock Performance

MRKR stock opened at $1.47 on Tuesday. Marker Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.07. The stock has a market capitalization of $24.50 million, a price-to-earnings ratio of -1.20 and a beta of 1.42. The stock’s fifty day moving average is $1.66 and its two-hundred day moving average is $1.28.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on MRKR. Zacks Research downgraded shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Wall Street Zen raised shares of Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Monday, December 22nd. HC Wainwright started coverage on shares of Marker Therapeutics in a research note on Monday, December 8th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a research report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $11.25.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in shares of Marker Therapeutics in the 2nd quarter worth approximately $33,000. Virtu Financial LLC acquired a new position in Marker Therapeutics in the third quarter worth approximately $25,000. Two Sigma Investments LP acquired a new position in Marker Therapeutics in the third quarter worth approximately $33,000. XTX Topco Ltd increased its holdings in shares of Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after buying an additional 36,269 shares in the last quarter. Finally, LPL Financial LLC increased its holdings in shares of Marker Therapeutics by 41.7% in the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after buying an additional 24,500 shares in the last quarter. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.